Neurocrine Biosciences (NBIX) Free Cash Flow Growth (1y) (2011 - 2026)
Neurocrine Biosciences (NBIX) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 10.34% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -13.65% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 56.40% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -5.85% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | -29.32% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 166.91% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 44.93% |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn | 124.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 166.91% |
| Dec 31, 2025 | 90.54% |
| Sep 30, 2025 | 20.25% |
| Jun 30, 2025 | 52.83% |
| Mar 31, 2025 | -54.58% |
| Dec 31, 2024 | 68.25% |
| Sep 30, 2024 | -24.26% |
| Jun 30, 2024 | -59.59% |
| Mar 31, 2024 | 194.67% |
| Dec 31, 2023 | -22.36% |
| Sep 30, 2023 | 149.29% |
| Jun 30, 2023 | 28.14% |
| Mar 31, 2023 | -190.53% |
| Dec 31, 2022 | 3,440.43% |
| Sep 30, 2022 | 71.72% |
| Jun 30, 2022 | 38.48% |
| Mar 31, 2022 | -149.66% |
| Dec 31, 2021 | -105.55% |
| Sep 30, 2021 | 340.29% |
| Jun 30, 2021 | -14.90% |